

- (51) **International Patent Classification:**
Not classified
- (21) **International Application Number:**
PCT/US2024/019231
- (22) **International Filing Date:**
08 March 2024 (08.03.2024)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/489,414 09 March 2023 (09.03.2023) US
63/614,102 22 December 2023 (22.12.2023) US
- (71) **Applicant:** TRIVENI BIO, INC. [US/US]; 99 Coolidge Avenue, Suite 450, Watertown, MA 02472 (US).
- (72) **Inventors:** DOVEY, Jennifer, L.; 99 Coolidge Avenue, Suite 450, Watertown, MA 02472 (US). CAPILI, Allan; 99 Coolidge Avenue, Suite 450, Watertown, MA 02472 (US). ZON, Leonard; 99 Coolidge Avenue, Suite 450, Watertown, MA 02472 (US). ENTOVA, Sonya; 99 Coolidge Avenue, Suite 450, Watertown, MA 02472 (US). NORDYKE, Christopher; 99 Coolidge Avenue, Suite 450, Watertown, MA 02472 (US). CALVINO, Jenna; 99 Coolidge Avenue, Suite 450, Watertown, MA 02472 (US). BORLAND,

Todd; 99 Coolidge Avenue, Suite 450, Watertown, MA 02472 (US). TANG, Ye; 99 Coolidge Avenue, Suite 450, Watertown, MA 02472 (US). HERRIN, Brantley; 99 Coolidge Avenue, Suite 450, Watertown, MA 02472 (US). LUNDE, Bradley; 7 Lucent Dr, Lebanon, NH 03766 (US). SHARKEY, Nathan; 7 Lucent Dr, Lebanon, NH 03766 (US).

(74) **Agent:** GE, Lingyin et al.; Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210-2206 (US).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,

(54) **Title:** DUAL INHIBITOR KALLIKREIN ANTIBODIES AND USES THEREOF




FIG. 1

(57) **Abstract:** Aspects of the application provide dual inhibitor anti-KLK5/KLK7 antibodies and methods of using the same for promoting barrier function and reducing inflammation, and treating conditions such as Netherton syndrome, eosinophilic esophagitis and atopic dermatitis.

SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*
- *with sequence listing part of description (Rule 5.2(a))*